Loading
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Regular session
$3.04
+$0.005 · +0.16%
Regular session · ET · Market data may be delayed.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Day range
Current $3.04
52-week range
Current $3.04
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
60
Mixed
Risk
71
High Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Day range
Current $3.04
52-week range
Current $3.04
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 3.32K USD | 11.41K USD | 11.41K USD | 10.05K USD |
| Gross profit | — | −3.32K USD | −11.41K USD | −11.41K USD | −10.05K USD |
| Research and development | 1.13M USD | 422.05K USD | 5.91M USD | 8.98M USD | 5.92M USD |
| Selling, general, and administrative | 1.35M USD | 3.21M USD | 5.9M USD | 6.49M USD | 5.93M USD |
| Operating expenses | 2.47M USD | 4.38M USD | 11.81M USD | 15.47M USD | 11.85M USD |
| Interest income | 369K USD | — | — | 100.87 USD | 68.13 USD |
| Interest expense | 6.01M USD | 150.02K USD | 145.15K USD | 100.87K USD | 68.13K USD |
| Depreciation and amortization | 55K USD | 3.32K USD | 11.41K USD | 11.41K USD | 10.05K USD |
| Operating income | −2.47M USD | −4.38M USD | −11.81M USD | −15.48M USD | −11.86M USD |
| Net income | −8.3M USD | −1.98M USD | −12.17M USD | −16.5M USD | −11.95M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
